Electra Therapeutics to Begin Trading on Nasdaq Following Sept. 17 IPO Pricing
Electra Therapeutics, a clinical-stage biotechnology company based in South San Francisco, is set to begin trading on the Nasdaq under the ticker ETRA following its initial public offering (IPO) pricing date of September 17, 2026. The firm focuses on developing antibody-based medicines for severe immune-mediated diseases and cancer using a novel approach involving signal regulatory proteins (SIRPs). Unlike traditional SIRP strategies that target blocking pathways in oncology, Electra aims to selectively eliminate pathogenic cells while preserving normal immune function. The IPO includes the offering of approximately 21.67 million shares at $14–$16 per share, with gross proceeds potentially reaching up to $346.7 million if priced at the top end. The company has no approved products and remains unprofitable, reporting a net loss of around $48.9 million as of June 30, 2026. Jefferies, TD Cowen, Evercore ISI, and Cantor Fitzgerald are acting as joint book-running managers for the offering.
Tickers: $ETRA
Topics: biotechnology clinical-stage company IPO